Drawing for FORTRIS

USPTO serial 78101010

FORTRIS

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
BLOHM, LINDA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FORTRIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark I. Peroff

G ROXANNE ELINGS GREENBERG TRAURIG21ST FL885 THIRD AVENEW YORK, NY 10022

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neuropathic pain, diabetic neuropathy, neurological disorders, neurdegenerative disorders, pain, and depression; neuroprotective agentABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 23, 2002ABN5ABANDONMENT - AFTER PUBLICATION—
Aug 20, 2002TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 31, 2002ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jul 2, 2002PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 12, 2002NPUBNOTICE OF PUBLICATION—
Apr 15, 2002CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 9, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance